Apollomics, Inc. · NASDAQ (us_market)
— · — · —
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2023-10-20$0.06 RISE2024-01-24$0.02 PEAK2024-01-26$0.03 98d | -64.8% 96d | Missed | Missed | — | — | +42.2% 2d | Missed |
DROP2023-08-15$0.07 RISE2023-12-21$0.02 PEAK2024-01-19$0.04 157d | -67.0% 128d | Missed | Missed | — | — | +74.0% 29d | Missed |
DROP2023-07-18$0.10 RISE2023-10-31$0.01 PEAK2023-11-29$0.05 134d | -86.8% 105d | Missed | Missed | — | — | +246.2% 29d | Missed |
DROP2023-03-30$0.12 RISE2023-05-31$0.06 PEAK2023-06-01$0.13 63d | -50.1% 62d | Missed | Missed | — | — | +109.0% 1d | Missed |
DROP2023-03-30$0.12 RISE2023-04-13$0.08 PEAK2023-06-01$0.13 63d | -34.5% 14d | Missed | Missed | — | — | +59.3% 49d | Missed |
No scored news yet for a sentiment trend.
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer, on March 30, 2026. The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corpor
Nasdaq Hearing Cancellation and Continued ListingFOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “
The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:APLM) and warrants (NASDAQ:APLMW) at 9:00 a.m. and 9:05 a.m. Eastern Time, respectively,
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most ch
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 318.5K | $6.37K | 0.00% | Unchanged | 2026-03-31 |